Purpose of review Myasthenia gravis is due to autoantibodies against components of the neuromuscular junction. Here, we analyzed the latest concepts of the physiopathological mechanisms and highlighted the recent findings about the immune-regulatory and etiological mechanisms.
INTRODUCTION
Myasthenia gravis is an autoimmune disease characterized by the presence of antibodies against muscle components of the neuromuscular junction (NMJ). In most cases, autoantibodies against the acetylcholine receptor (AChR) are found but other targets, such as muscle-specific kinase (MuSK) or lipoprotein-related protein 4 (LRP4), have been described ( Fig. 1) . Thus, several different entities can be defined with distinct physiopathological mechanisms.
If the triggering mechanism of this autoimmune response is not known, new developments involving environmental and genetic factors have been proposed. Dysregulation of immune cells leading to autoantibody production in myasthenia gravis is well documented [1, 2] . However, recent data suggest that microRNA (miRNA) could play an important role in modulating the immune response.
In this review, we analyze the latest concepts of the pathophysiology of myasthenia gravis according to various entities, including the role of immunological, genetic and environmental factors.
Myasthenia gravis with anti-AChR antibodies: central role of complement components
The form of myasthenia gravis with anti-AChR antibodies (AChR-MG) is the most common type and has been largely described [5, 8] . The classical complement pathway is mainly involved in the pathogenesis of AChR-MG (Fig. 2) . Formation of the membrane attack complex is initiated by activated C3; it colocalizes with AChR and causes severe structural injury of endplates and lyses the postsynaptic membrane, which ultimately disperses and depletes AChR at the NMJ [9] .
The use of mice deficient in molecules involved in the complement cascade has shed light on the role of complement in the physiopathological mechanisms of myasthenia gravis. Mouse deficient in C3, C4 and C5 factors are resistant to experimental autoimmune myasthenia gravis (EAMG) [10] , whereas more severe symptoms are observed in mice deficient in regulators of complement, such as DAF/ CD55, Protectin/CD59 or Crry [11] [12] [13] (Fig. 2 ).
Modulation of complement activity represents a potentially effective approach to modify autoimmune processes in myasthenia gravis. An improvement of clinical symptoms in EAMG is observed after treatment with hybrid molecules for complement regulators, such as scFv-DAF [14] ) or Crry-Ig [15] , or with complement inhibitors such as anti-C5 [16] . A siRNA-mediated suppression of C2 following established disease can also effectively contribute to the remission of EAMG [17 && ]. Eculizumab, a well tolerated humanized monoclonal antibody that prevents the enzymatic cleavage of C5, has recently been tested in myasthenia gravis patients. Overall change in mean quantitative myasthenia gravis total score is significantly different between eculizumab and placebo. These data suggest that eculizumab may have a role in treating severe, refractory myasthenia gravis [18 && ]. These findings demonstrate that novel therapy methods based on inhibition or modulation of the classical complement pathway represent attractive approaches for myasthenia gravis patients.
Pathogenic mechanisms of muscle-specific kinase autoantibodies
Anti-MuSK antibodies were first described in 2001 [6] . In myasthenia gravis patients, most anti-MuSK
KEY POINTS
Autoantibodies against AChR, MuSK and LRP4 differentially alter neuromuscular transmission in myasthenia gravis. The management of the patients needs to be adapted accordingly.
Novel susceptibility loci have been identified in myasthenia gravis, such as the transcription factor (TCF19) and TNF-a-induced protein 3 interacting protein 1 (TNIP1).
Increased number of CXCR5 þ ICOSL þ T cells and AChR-CD21 þ B cells in AChR-MG patients are linked to the disease activity, and could be interesting monitoring biomarkers.
dsRNA could contribute to the cause of myasthenia gravis, supporting the hypothesis of a viral-mediated mechanism in the onset of myasthenia gravis.
Changes in the level of miRNA expression might significantly alter the regulation of immune cells in myasthenia gravis. ] showed that anti-MuSK antibodies from myasthenia gravis patients induce a progressive decrease in the area and density of postsynaptic AChRs in the five muscles examined. These results suggest that the primary myasthenogenic action of anti-MuSK IgG is to cause a decrease in postsynaptic AChR density.
The use of anticholinesterase treatment is in doubt for MuSK-MG patients. Anti-MuSK antibodies induce a cholinergic hypersensitivity in MuSKinjected mice similar to that observed in MuSK-MG patients, and a decrease in both acetylcholine EAMG in KO mice for:  CD59 CD55, Crry  C3, C4, C5 C2, C5 Inhibition of:
C4b C2a ]. Finally, the data showing that 3,4-DAP may be effective as a symptomatic therapy in MuSK-MG have potential consequences on the management of these patients.
Seronegative myasthenia gravis patients: not so seronegative anymore
In patients without anti-AChR or anti-MuSK, the presence of other antibodies targeting NMJ proteins has been investigated ( Fig. 1 ).
Myasthenia gravis patients with lipoprotein-related protein 4 antibodies
Anti-LRP4 antibodies have been recently demonstrated in myasthenia gravis patients without anti-MuSK or anti-AChR antibodies. LRP4 interacts with agrin that binds and activates MuSK, which in turn leads to the aggregation of AChRs at the NMJ (Fig. 1 ). The percentage of myasthenia gravis patients with anti-LRP4 antibodies among doublenegative myasthenia gravis patients varies between 2 and 50% according to studies [30 & ,31 & ]. Anti-LRP4 antibodies seem to alter the clustering of the AChRs. These antibodies are of the IgG1 type, and might thus interact with the complement components.
Myasthenia gravis patients with antibodies detectable in cell-based assays
Sixty per cent of myasthenia gravis patients so far considered as seronegative, including ocular myasthenia gravis, have also antibodies that do not bind efficiently to AChRs in solution but bind clustered AChRs at the muscle cell surface [32] . These antibodies are predominantly IgG1, and are therefore able to activate the complement cascade, and are potentially pathogenic in vivo [33 && ]. The cell-based assay that detects the antibodies against clustered AChR also revealed the presence of antibodies against both agrin and collagen Q in some seronegative myasthenia gravis patients [34] . Another study strengthens the idea that seronegative patients develop an autoimmune response against AChR. Using overlapping synthetic peptides encompassing the extracellular part of the human a-AChR-chain, Oshima et al. [35] found that most seronegative patients exhibit an anti-AChR autoimmune T lymphocyte response.
DYSREGULATION OF THE IMMUNE SYSTEM IN MYASTHENIA GRAVIS
Deficient immunoregulation is consistently observed in myasthenia gravis. The abnormalities of the T cell response have been shown by the assessment of activation markers, inflammatory features and imbalance between the different T cell subsets, including Th17 and regulatory T cells [36] .
Active development of ectopic germinal centers
The interaction between T and B cells is a decisive point for antibody production. The ectopic development of germinal centers within the thymus of AChR-MG patients is well known [1] . Recently, it was demonstrated that the myasthenia gravis thymus displays all the characteristics of secondary lymphoid organs with the development of high endothelial venules (HEVs) expressing stromal cell-derived factor 1 (SDF1)/CXCL12 [37 & ]. Thus, ectopic thymic HEVs, together with increased expression of the B-cell chemoattractant chemokine, CXCL13, by thymic epithelial cells [38] and of CCL21 by lymphatic vessels [39] allows the recruitment of peripheral cells and the development of germinal centers. Follicular helper T (Tfh) cells are normally located in germinal centers and promote B cells to produce antibodies [40] . Tfh cells that highly express CXCR5 and inducible T-cell COStimulator (ICOS) are the most potent inducers of IgG production and secrete large amounts of CXCL13 [41] . Using these markers, Luo et al. [42] have recently demonstrated that the frequency of Tfh cells in the peripheral blood of myasthenia gravis patients is significantly higher compared with healthy controls, and is correlated with the levels of serum anti-AChR antibodies and of CXCL13 and interleukin (IL)-21. These results confirm a previous article describing a correlation between the frequency of Tfh cells and disease activity [43] . A positive correlation between the serum anti-AChR antibody level and the number of CD21 þ B cells specific for AChR has also been shown [44] .
Altogether, these results indicate that the increased number of CXCR5 þ ICOSL þ T cells and AChR-CD21 þ B cells in myasthenia gravis patients is directly linked to the disease activity, and these could be interesting monitoring biomarkers.
microRNAs as regulators of immune activation
Using a Chinese cohort, 34 miRNAs were found differently expressed in myasthenia gravis patients compared with healthy controls [45 && ]. A correlation between the decrease in miR-320a and the increase in the proinflammatory cytokines [IL-2, interferon (IFN)-g, IL-17, IL-6] could be shown. By targeting mitogen-activated kinase 1, miR-320a inhibited the extracellular signal-regulated kinase pathway, but strengthened the c-jun-N-terminal kinase pathway, which could explain the decreased expression of the proinflammatory cytokines. The link between the changes in this miRNA and the physiopathological mechanisms in myasthenia gravis needs further investigation.
Significantly decreased levels of let-7 family miRNA compared with healthy controls were shown [46 & ]. There is a negative correlation between the levels of let-7c and IL-10 mRNA in peripheral blood mononuclear cells from myasthenia gravis patients. Interestingly, in a very recent article, Gandhi et al. [47 & ] showed that the let-7 family of miRNAs differentiates subgroups of multiple sclerosis patients from healthy controls. Let-7 can also modulate Fas expression and the sensitivity of Fas-mediated apoptosis [48] . As Fas is upregulated in T cells from myasthenia gravis patients [49] , one could speculate that changes in expression of let-7 could explain the dysregulation of Fas in myasthenia gravis patients.
These findings on miRNA lead the way on this very promising new research avenue. Changes in the level of miRNA expression that could result from an external event, such as infection, might significantly alter the regulation of immune cells.
ETIOLOGICAL MECHANISMS OF MYASTHENIA GRAVIS
Myasthenia gravis is a multifactorial disease. The onset of the disease is not clearly defined and is more likely to be linked to a combination of predisposing and environment factors.
Genetic associations
Several genetic studies demonstrate the link between certain human leukocyte antigen (HLA) alleles and myasthenia gravis. Other genetic associations with autoimmune myasthenia gravis have been made on the a-AChR promoter and on genes with immune functions as fully reviewed by Cavalcante et al. [2, 8] . Recently, a study has demonstrated a homozygous single nucleotide variant related to the ecto-NADH oxidase 1 (ENOX1) gene in a kindred with parental consanguinity with lateonset myasthenia gravis. ENOX proteins catalyze hydroquinone oxidation and protein disulfide-thiol interchange. The ENOX1 variant might predispose to myasthenia gravis by affecting the motor endplate and/or the autoimmune response. However, the exact role and implication of ENOX1 in myasthenia gravis need to be investigated in larger cohorts of patients [50 & ]. A recent genome-wide association study on north European early-onset myasthenia gravis (EOMG) patients described the strongest association in the HLA class I region at rs775064 [51 && ] This variant is located in the gene encoding the transcription factor TCF19 that is involved in cell proliferation or differentiation and is upregulated in human proB and preB cells. It is also highly expressed in germinal center cells [52] . Two other loci have also been extracted corresponding to PTPN22 and to tumor necrosis factor-a (TNF-a)induced protein 3 interacting protein 1 (TNIP1) [51 && ]. A TNIP1 polymorphism has also been related to chronic inflammatory diseases [53] . TNIP1 is a signaling transduction protein that inhibits transduction by transmembrane and nuclear receptors, such as TNF-a receptor, Toll-like receptors (TLRs) and retinoic acid receptors. These receptors play key roles in regulating inflammation and inflammatory diseases [54] . Mice with a knockin mutation disrupting the ubiquitin-binding of TNIP1 develop the hallmarks of autoimmunity, including spontaneous formation of germinal centers, isotype switching and production of autoreactive antibodies [55] . Altogether, this suggests that this TNIP1 variant might be associated with an exacerbated inflammatory status.
Beyond pure genetic analyses, numerous studies are also in progress to determine the impact of epigenetic modifications on selected genes that might play a central role in autoimmune diseases.
Environmental risk factors
Environmental factors are also put forward to explain a higher risk of developing autoimmune diseases [2] . Viral infections have been suspected for years to play a role in myasthenia gravis [2, 56] . The difficulty to relate myasthenia gravis to a pathogen infection is because of the fact that myasthenia gravis symptoms probably occur well after a possible triggering infection. However, antiviral signature can be observed in the myasthenia gravis thymus. Overexpression of numerous IFN-Iinduced genes [57, 58] but also of TLR4 [59] and TLR3, protein kinase R, IRF7, IRF5 and IFN-b, has been described [60 && ]. In parallel, it was demonstrated that double-stranded RNA (dsRNA) signaling induced by Poly(I:C) specifically triggers the overexpression of a-AChR in thymic epithelial cells. This induction is mediated through TLR3 and protein kinase R, and by the release of IFN-b. In addition, Poly(I:C) injections specifically increase thymic expression of a-AChR in mice and lead to a significant production of serum anti-AChR antibodies and a specific proliferation of B cells to AChR. As anti-AChR antibodies are highly specific for myasthenia gravis and are pathogenic, dsRNA signaling activation could contribute to the cause of myasthenia gravis. This observation could be related to the presence of Epstein-Barr virus (EBV)-positive cells in myasthenia gravis thymus [61] Indeed, EBV encodes small RNAs [Epstein-Barr virus (EBV)-encoded RNAs] that trigger TLR3 signaling and induce IFN-I and proinflammatory cytokine expression, similarly to Poly(I:C) [62] . Moreover, a study last year [63 & ] showed higher levels of antibodies against the type 1 nuclear antigen of EBV in the serum of EOMG patients compared with healthy controls.
Changes regarding the level of expression of TLRs have also been detected on peripheral blood mononuclear cells suggesting that TLRs may contribute to myasthenia gravis pathogenesis. The role and the consequences of these changes are not yet clear. Nevertheless, a positive correlation between the mRNA levels of TLR9 and the clinical severity of myasthenia gravis is observed [64] .
Growing evidence of chronic inflammation, TLR activation and persistent viral infections in the thymus of myasthenia gravis patients strongly supports the hypothesis that, in the context of a genetic susceptible background, the intrathymic innate immune responses to pathogen infections might contribute to myasthenia gravis cause.
CONCLUSION
Even though myasthenia gravis has been actively studied since the 1970s and despite the discovery of the anti-AChR autoantibodies, recent investigations show that research on myasthenia gravis is still very active. This is especially obvious regarding the different myasthenia gravis entities and their distinct physiopathological mechanisms. New developments regarding the role of small RNAs (miRNAs) in the modulation of immune functions have been initiated and deserve future investigation, especially with a link to the etiological mechanisms, as the activation of dsRNA signaling pathways has been shown to be able to induce the disease in mice [60 && ]. 
